Evidence map›Paper›PMID 34213614›Full record

ArticleJournal of neurology2022

NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand.

Wajih Bukhari, Elham Khalilidehkordi, Deborah F Mason, Michael H Barnett, Bruce V Taylor, Marzena Fabis-Pedrini, Allan G Kermode, Sankar Subramanian, Patrick Waters, Simon A Broadley and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. NMOSD and MOGAD: an evolving disease spectrum.Nature reviews. Neurology · 2024
    Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 11 institutions in 3 countries.

Wajih BukhariMenzies Health Institute Queensland, School of Medicine, Griffith University, Gold Coast Campus, Brisbane, QLD, 4222, Australia.
Elham KhalilidehkordiMenzies Health Institute Queensland, School of Medicine, Griffith University, Gold Coast Campus, Brisbane, QLD, 4222, Australia.
Deborah F MasonNew Zealand Brain Research Institute, Christchurch, 8011, New Zealand.
Michael H BarnettBrain and Mind Centre, University of Sydney, Camperdown, NSW, 2006, Australia.
Bruce V TaylorMenzies Institute for Medical Research, University of Tasmania,, Hobart, TAS, 7000, Australia.
Marzena Fabis-PedriniPeron Institute, University of Western Australia, Nedlands, WA, 6009, Australia.
Allan G KermodePeron Institute, University of Western Australia, Nedlands, WA, 6009, Australia.
Sankar SubramanianGeneCology Research Centre, University of Sunshine Coast, Sippy Downs, QLD, 4556, Australia.
Patrick WatersNuffield Department of Clinical Neurosciences, John Radcliffe Infirmary, University of Oxford, Oxford, OX3 9DU, UK.
Simon A BroadleyMenzies Health Institute Queensland, School of Medicine, Griffith University, Gold Coast Campus, Brisbane, QLD, 4222, Australia. simon.broadley@griffith.edu.au.
Australian and New Zealand NMO Collaboration
Gold Coast Hospital · AUUniversity of Sydney · AUUniversity of the Sunshine Coast · AUUniversity of Western Australia · AUGriffith University · AUUniversity of Tasmania · AUCanterbury District Health Board · NZJohn Radcliffe Hospital · GBPerron Institute for Neurological and Translational Science · AUUniversity of Otago · NZUniversity of Oxford · GB

Funding

Multiple Sclerosis Research Australia 11-038
6 · The paper itself

Abstract

backgroundWe studied the prevalence of neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS) in Indigenous populations of Australia and New Zealand with the aim of assessing potential differences.

methodsCases of possible NMOSD and MS were collected from Australia and New Zealand. Clinical details, MR imaging, and serologic results were used to apply 2015 IPND diagnostic criteria for NMOSD and 2010 McDonald criteria for MS. Frequencies of self-determined ethnic ancestry were calculated for confirmed NMOSD, suspected NMOSD, and MS. Prevalence rates for NMOSD and MS according to ancestry were compared.

resultsThere were 75 cases with NMOSD, 89 with suspected NMSOD, and 101 with MS. NMOSD cases were more likely to have Asian, Indigenous, or Other ancestry compared to suspected NMOSD or MS. There were no differences in the clinical phenotype of NMOSD seen in Indigenous compared to European ancestry populations. Per 100,000, the prevalence estimate for NMOSD in people with Māori ancestry was 1.50 (95% CI 0.52-2.49) which was similar to those with Asian ancestry 1.57 (95% CI 1.15-1.98). NMOSD prevalence in Australian Aboriginal and Torres Strait Islander populations was 0.38 (95% CI 0.00-0.80) per 100,000.

conclusionThe prevalence of NMOSD in the Māori population is similar to South East Asian countries, reflecting their historical origins. The prevalence of MS in this group is intermediate between those with South East Asian and European ancestry living in New Zealand. Both NMOSD and particularly MS appear to be uncommon in the Indigenous populations of Australia.

Indexed as

Multiple SclerosisNeuromyelitis OpticaAustraliaAustralian Aboriginal and Torres Strait Islander PeoplesHumansIndigenous PeoplesNew ZealandPrevalenceAboriginal and Torres Strait IslanderAquaporinGeneticsMāoriNeuromyelitis optica

Identifiers

PMID34213614
OpenAlexW3176549978

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.